CCDC47

Across TCGA pan-cancer cohorts, CCDC47 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC47 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CCDC47 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC47 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

DLBC, BLCA, and SKCM are the cancer types where CCDC47 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	All	0.138	0.799	<.001	33	view →
BLCA	OS	Median	II,III,IV	1.000	0.421	.021	22	view →
SKCM	DFS	Median	All	0.130	0.728	.003	15	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.622	.014	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCDC47–DLBC (DFS)

Open the DLBC breakdown →